CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Allogeneic MSCbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04626583
NCT04626583Phase 1Completed
CompareCT.gov

Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells for Promoting Corneal Repair

University of Illinois at Chicago·interventional·Posted Nov 12, 2020·Updated Dec 16, 2024

In Brief

A Phase 1 clinical trial evaluating Allogeneic MSC for Mesenchymal Stromal Cells and 3 related conditions. Completed, enrolled 8 participants across 4 sites.

Detailed Summary

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesenchymal Stromal Cells, Cornea, Safety, Corneal Defect
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedNov 12, 2020
Enrollment StartMar 5, 2021
Primary CompletionApr 21, 2023
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 5.6 years ago

Interventions

Allogeneic MSCbiological

Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells